Opportunity ID: 343289

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-HD-23-030
Funding Opportunity Title: HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R01 Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Education
Health
Income Security and Social Services
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.242 — Mental Health Research Grants
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Aug 29, 2022
Last Updated Date: Aug 29, 2022
Original Closing Date for Applications: Dec 07, 2022
Current Closing Date for Applications: Dec 07, 2022
Archive Date: Jan 12, 2023
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Public and State controlled institutions of higher education
Small businesses
Special district governments
City or township governments
Native American tribal governments (Federally recognized)
For profit organizations other than small businesses
Private institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Public housing authorities/Indian housing authorities
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
State governments
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Native American tribal organizations (other than Federally recognized tribal governments)
Independent school districts
County governments
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name: National Institutes of Health
Description: This Funding Opportunity Announcement (FOA) invites grant applications to study the impact of opioids, alone or in combination with other substances of misuse, on placenta function and neurodevelopment during pregnancy and in the first year of life. Clinical Trials are not permitted for this FOA; researchers proposing Basic Experimental Studies with Humans (BESH) should consider the companion FOA, RFA-HD-23-032, HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R01 Basic Experimental Studies with Humans Required).
Link to Additional Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-23-030.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH Grants Information
grantsinfo@nih.gov
Email:grantsinfo@nih.gov

Version History

Version Modification Description Updated Date

Related Documents

Packages

Agency Contact Information: NIH Grants Information
grantsinfo@nih.gov
Email: grantsinfo@nih.gov
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-G Use for due dates on or before January 24, 2023 PKG00276590 Nov 07, 2022 Jan 24, 2023 View
FORMS-H Use for due dates on or after January 25, 2023 PKG00277875 Nov 07, 2022 Dec 07, 2022 View

Package 1

Mandatory forms

343289 RR_SF424_5_0-5.0.pdf

343289 PHS398_CoverPageSupplement_5_0-5.0.pdf

343289 RR_OtherProjectInfo_1_4-1.4.pdf

343289 PerformanceSite_4_0-4.0.pdf

343289 RR_KeyPersonExpanded_4_0-4.0.pdf

343289 PHS398_ResearchPlan_4_0-4.0.pdf

343289 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

343289 RR_Budget_3_0-3.0.pdf

343289 RR_SubawardBudget30_3_0-3.0.pdf

343289 PHS398_ModularBudget_1_2-1.2.pdf

343289 PHS_AssignmentRequestForm_3_0-3.0.pdf

Package 2

Mandatory forms

343289 RR_SF424_5_0-5.0.pdf

343289 PHS398_CoverPageSupplement_5_0-5.0.pdf

343289 RR_OtherProjectInfo_1_4-1.4.pdf

343289 PerformanceSite_4_0-4.0.pdf

343289 RR_KeyPersonExpanded_4_0-4.0.pdf

343289 PHS398_ResearchPlan_5_0-5.0.pdf

343289 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

343289 RR_Budget_3_0-3.0.pdf

343289 RR_SubawardBudget30_3_0-3.0.pdf

343289 PHS398_ModularBudget_1_2-1.2.pdf

343289 PHS_AssignmentRequestForm_3_0-3.0.pdf

2025-07-13T16:07:53-05:00

Share This Post, Choose Your Platform!

About the Author: